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T
A B S T R A C T   
Background: Microvascular and macrovascular thrombotic events are among 
the hallmarks of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is considered an important driver of pulmonary and extra-
pulmonary manifestations of COVID-19. The optimal management strategy to prevent thrombosis in critically-ill patients with COVID-19 remains unknown. 
Methods: The Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial 
(INSPIRATION) and INSPIRATION-statin (INSPIRATION-S) studies test two independent hypotheses within a randomized controlled trial with 2 × 2 factorial design. 
Hospitalized critically-ill patients with reverse transcription polymerase chain reaction confirmed COVID-19 will be randomized to intermediate-dose versus standard 
dose prophylactic anticoagulation. The 600 patients undergoing this randomization will be screened and if meeting the eligibility criteria, will undergo an additional 
double-blind stratified randomization to atorvastatin 20 mg daily versus matching placebo. The primary endpoint, for both hypotheses will be tested for superiority 
and includes a composite of adjudicated acute arterial thrombosis, venous thromboembolism (VTE), use of extracorporeal membrane oxygenation, or all-cause death 
within 30 days from enrollment. Key secondary endpoints include all-cause mortality, adjudicated VTE, and ventilator-free days. Key safety endpoints include major 
bleeding according to the Bleeding Academic Research Consortium definition and severe thrombocytopenia (platelet count < 20,000/fL) for the anticoagulation 
hypothesis. In a prespecified secondary analysis for non-inferiority, the study will test for the non-inferiority of intermediate intensity versus standard dose antic-
oagulation for major bleeding, considering a non-inferiority margin of 1.8 based on odds ratio. Key safety endpoints for the statin hypothesis include rise in liver 
enzymes > 3 times upper normal limit and clinically-diagnosed myopathy. The primary analyses will be performed in the modified intention-to-treat population. 
Results will be tested in exploratory analyses across key subgroups and in the intention-to-treat and per-protocol cohorts. 
Conclusions: INSPIRATION and INSPIRATON-S studies will help address clinically-relevant questions for antithrombotic therapy and thromboinflammatory therapy 
in critically-ill patients with COVID-19.  
1. Introduction 
Coronavirus disease-2019 (COVID-19) is an acute viral illness 
caused by the severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV-2). It has caused a global pandemic, afflicting > 23.5 million pa-
tients worldwide and leading to > 810,000 deaths [1–5]. 
Although initially considered a respiratory illness, COVID-19 has 
multi-system manifestations [6]. Micro and macrothrombosis are 
among the hallmarks of the disease pathophysiology [7,8]. Acute ill-
ness, immobility, cytokine storm, platelet hyperreactivity [9], and di-
rect viral thrombogenicity may predispose patients to a prothrombotic 
state [7]. Depending on whether the systematic screening is utilized, 
Table 1 
Inclusion and exclusion criteria.    
Anticoagulation hypothesis 
Inclusion criteria Exclusion criteria   
• Adult patients (≥18 years), with RT-PCR-confirmed COVID-19admitted to ICU within 
7 days of initial hospitalization, who do not have another firm indication for 
anticoagulation (such as mechanical valve, high-risk AF, VTE, or left ventricular 
thrombus),who are not enrolled in another blinded randomized trial, and are willing to 
participate in the study and provide informed consent.  
• Estimated survival of at least 24 h at the discretion of enrolling physician  
• Weight  <  40Kg  • Use of systemic anticoagulation for another indication (mechanical valve, 
ECMO, AF, left ventricular thrombus, or diagnosed VTE)  
• Overt bleeding at the day of enrollment  • Known major bleeding within 30 days (according to the Bleeding Academic 
Research Consortium (BARC) definition, Appendix A)  
• Platelet count  < 50,000/Fl  • Pregnancy (as confirmed by beta-HCG testing among female patients   
< 50 years)  
• History of heparin induced thrombocytopenia or immune thrombocytopenia  • Ischemic stroke within the past 2 weeks  • Major head or spinal trauma in the past 30 days  • Craniotomy/major neurosurgery within the past 3 months  • Known brain metastases or vascular malformations (aneurysm)  • Presence of an epidural, spinal or pericardial catheter  • Major surgery other than neurosurgery within 14 days prior to enrollment  • Coexistence of severe obesity (weight  >  120Kg or BMI  >  35Kg/M2 along 
with severe renal insufficiency defined as CrCl < 30 mL/min)  
• Allergic reaction to study medications  • Lack or withdrawal of informed consent     
Statin hypothesis 
inclusion criteria Exclusion criteria   
• Patients enrolled for the anticoagulation randomization  • Willingness to participation in the study and providing informed 
consent  
• Baseline liver function tests > 6 times upper normal limits  • Total creatine kinase > 500 U/L  • Active liver disease (LFT  >  3 times upper normal limit plus histologic finding including cirrhosis or 
inflammation or necrosis)  
• Routine use of statins prior to the index hospitalization  • Previous documented statin intolerance 
Beta-HCG: human chorionic gonadotropin, BMI: Body Mass Index, CrCl: Creatinine Clearance, CK: Creatine kinase, COVID 19: coronavirus disease 2019, ICU: 
intensive care unit, LFT: liver function test, RT-PCR: reverse transcriptase polymerase chain reaction (PCR), ULN: upper limit of normal, VTE: venous throm-
boembolism.  
B. Bikdeli, et al.   Thrombosis Research 196 (2020) 382–394
383
Fig. 1. Study flow diagram.  
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the studied population (wards versus intensive care units) and the use 
of thromboprophylaxis, the reported incidence of thrombotic events in 
patients with COVID-19 varies widely [10–18]. Thrombotic events may 
occur in the venous or arterial circulations, although venous throm-
boembolism (VTE) constitutes the predominant thrombotic condition 
[14]. Post-mortem studies have confirmed deep vein thrombosis, as 
well as pulmonary micro and macrothrombosis in patients with severe 
COVID-19, as the unexpected cause of death in some instances [19,20] 
[21]. 
The optimal antithrombotic regimen during hospitalization in these 
patients remains unknown [8]. For hospitalized patients with COVID- 
19, the majority of participants in a multinational panel of experts [7], 
as well as the guidelines from the World Health Organization, the Na-
tional Institute of Health and the American College of Chest Physicians 
[12,22,23] recommend standard-dose prophylactic anticoagulation. 
However, some studies have suggested that high risk of VTE may persist 
Table 2 
Simplified dosing strategies for intermediate dose (intervention arm in first hypothesis) applied in study sites.          
Intermediate dose anticoagulation Standard dose prophylaxis 
Weight (kg) CrCl1  >  30 mg/dL 
enoxaparin 
15  <  CrCl ≤ 30 mg/dL 
enoxaparin 
CrCl ≤ 15 mg/dL UFH CrCl1  >  30 mg/dL 
enoxaparin 
15  <  CrCl ≤ 30 mg/dL 
enoxaparin 
CrCl ≤ 15 mg/dL UFH  
41–50 50 mg daily 40 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
51–60 60 mg daily 40 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
61–70 70 mg daily 40 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
71–80 80 mg daily 40 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
81–90 90 mg daily 50 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
91–100 100 mg daily 50 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
101–110 110 mg daily 60 mg daily 10,000 U SC BID 40 mg daily 30 mg daily 5000 U SC BID 
111–120 120 mg daily Excluded*  Excluded* 
121–130 80 mg BID 40 mg BID 
131–140 90 mg BID 40 mg BID 
141–150 90 mg BID 40 mg BID 
151–160 100 mg BID 40 mg BID 
161–170 100 mg BID 40 mg BID 
171–180 110 mg BID 40 mg BID 
CrCl: creatitine clearance. Due to complexity of escalated dosing, and rarity of the coexistence of severe renal insufficiency (CrCl ≤30 mg/dL) and severe obesity 
(weight  >  120Kg) in the enrolling centers, the setting committee made an a priori decision to exclude these patients from enrollment.  
Table 3 
Study endpoint definitions.    
Endpoint Definition  
Deep venous thrombosis Any deep vein thrombosis diagnosed in the upper (internal jugular, subclavian, axillary/brachial), or lower extremity (iliac, femoral/ 
popliteal, gastrocnemius, peroneal, posterior tibial) or the inferior vena cava or deep splanchnic veins based on ultrasonography, or 
contrast-enhanced vascular imaging, including computed tomography or angiography; or vascular magnetic resonance imaging. 
Pulmonary embolism Any pulmonary embolism diagnosed on CT angiography, V/Q scan, invasive pulmonary angiography, echocardiography (thrombus 
visualized in the main pulmonary artery), or at autopsy. 
Undergoing ECMO Use of veno-venous or veno-arterial extracorporeal membrane oxygenation. 
Type 1 myocardial infarction (T1MI) Rise and/or fall in cardiac troponin values with at least on value above the 99th percentile upper reference limits with at least one of the 
followings; symptoms of ischemia, or new or presumed new ischemic ECG change, or Development of pathologic Q waves on the ECG, or 
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent ischemic etiology; 
confirmed by coronary angiography, intravascular imaging or autopsy.a 
Ischemic stroke An acute episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction and verified by dedicated brain 
imaging and confirmed by neurology consultation. 
Hemorrhagic stroke A focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma and verified by dedicated 
brain imaging. 
Acute limb ischemia Sudden decrease in limb perfusion that threatens limb viability with confirmed arterial obstruction based on duplex ultrasonography or 
contrast-enhanced vascular imaging, including computed tomography or angiography; or vascular magnetic resonance imaging. 
Ventilator free days Difference between total number of days alive post-enrollment and total number of days on invasive mechanical ventilation 
Atrial fibrillation New incident atrial fibrillation identified on electrocardiogram, or telemetry monitoring 
Renal replacement therapy Undergoing venovenous hemofiltration, hemodialysis, or peritoneal dialysis in patients without prior history of dialysis 
All-cause death Death due to any causes within the first 30 days. Considering the inaccuracies with adjudication of the cause of death in critically-ill 
patients with COVID-19 in the absence of systematic autopsy, the steering committee made the decision not to adjudicate the cause of 
death. 
ICU length of stay Total number of days spent in the ICU 
Discharge from ICU Alive discharge from the ICU 
Major bleeding BARC 3 or 5 bleeding (3: decrease in the hemoglobin of  > 3 g per deciliter, any transfusion, cardiac tamponade, or intracranial or 
ocular involvement; 5: fatal) 
Clinically-relevant non-major bleeding Clinically-significant bleeding that warranted attention from the medical personnel, but not fulfilling criteria for major bleeding 
Severe thrombocytopenia Incident thrombocytopenia with platelet count  < 20,000/fL 
Rise in liver enzyme Acute rise in liver enzymes > 3 times the upper reference limit 
Clinically diagnosed myopathy New myopathy diagnosed by the treating clinicians based on clinical and laboratory findings. 
All endpoints will be adjudicated by the clinical events committee, blinded to group assignment. 
Abbreviations: BARC: Bleeding Academic Research Consortium, CT: computed tomography, ECMO: extracorporeal membrane oxygenation, ICU: intensive care unit, 
V/Q: Ventilation perfusion. 
a Due to frequent elevation of cardiac troponins in the setting of COVID-19 for reasons other than COVID-19, and prior reports for non-specific electrocardio-
graphic changes in the setting of COVID-19, the Streeting committee decided to designate T1MI only if presence of cardiac biomarker elevations, electrocardiographic 
abnormalities or even wall motion abnormalities were verified by coronary angiography, intravascular imaging, or autopsy.  
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despite the routine use of standard prophylactic anticoagulation. Con-
sequently, some experts suggest prescribing higher doses or frequencies 
of antithrombotic therapy [13,14,24–26]. Some health systems have 
instituted higher doses of anticoagulation, aligned with retrospective 
analyses that suggested lower mortality associated with more intense 
anticoagulation [27,28]. However, limited trial data exist to inform 
clinical practice. This is especially important because more intense 
anticoagulation is associated with an increased risk of bleeding. 
In addition, the exuberant inflammatory response is known to play a 
role in the pathophysiology of acute respiratory distress syndrome 
(ARDS) [29] and especially that of COVID-19 [30,31]. Animal studies 
have shown that the inhibition of 3-hydroxy-3-methylglutarylcoenzyme 
A (HMG-CoA) reductase could modify several underlying mechanisms 
implicated in the development of ARDS [32]. In the HARP-2 trial, 
simvastatin, compared with placebo, was safe but did not improve the 
survival in patients with ARDS [33]. Subsequent analyses indicated 
interesting hypothesis-generating information for the potential role of 
statins in mitigating the outcomes in patients with hyperinflammatory 
sub-phenotype of ARDS [34]. 
This manuscript summarizes the design features of the INtermediate 
versus Standard-dose Prophylactic anticoagulation In cRitically-ill 
pATIents with COVID-19: An opeN label randomized controlled trial 
(INSPIRATION) and INSPIRATION-statin (INSPIRATION-S) studies. In a 
2 × 2 factorial design randomized controlled trial, we aim to in-
vestigate the safety and efficacy of two pharmacological regimens (in-
termediate-dose versus standard-dose anticoagulation; and statin 
therapy with atorvastatin 20 mg/daily versus matching placebo) on 
outcomes of critically-ill patients with COVID-19. 
2. Methods 
2.1. Trial design and study sites 
INSPIRATION/INSPIRATION-S will be a multicenter 2 × 2 factorial 
design randomized controlled trial with allocation sequence conceal-
ment and blinded endpoint adjudication. The allocation ratio will be 
1:1 for both the anticoagulation and the statin components. The first 
randomization (anticoagulation) is open-label, and the second rando-
mization (use of atorvastatin) is placebo-controlled and double blind. 
The study sites include 7 teaching hospitals in 2 cities in Iran (Tehran 
and Tabriz): Masih Daneshvari Hospital, Hazrate Rasool-e Akram 
General Hospital, Modarres Hospital, Sina Hospital, Firoozgar General 
Hospital and Imam Khomeini Hospital (all in Tehran, Iran), and Imam 
Reza Hospital (in Tabriz, Iran). Iran is among the countries facing a 
second surge of COVID-19 and the chosen hospitals represent high- 
volume teaching referral centers. Study design, coordination and 
follow-up are performed with support from Rajaie Cardiovascular 
Medical and Research Center and Tehran Heart Center. Prior experi-
ence from Iran, as well as centers elsewhere in the world suggested that 
the disease wave in COVID-19 may shift fairly quickly, with practical 
challenges for patient recruitment and follow-up. Therefore, all at-
tempts were made to design the study with rigor, but also as quickly as 
possible. 
The study protocol was reviewed and approved by the institutional 
review board at Rajaie Cardiovascular Medical and Research Center, 
Tehran, Iran, and accepted by all other participating study sites. The 
study goals and interventions will be discussed with eligible subjects (or 
their healthcare proxies). For subjects agreeing to participate, written 
informed consent will be obtained. The trial oversight will be under-
taken by the Data Safety and Monitoring Board comprised of clinicians 
and an independent statistician, not involved with the design or con-
duct of the trial. Patient enrollment began on July 29, 2020 and en-
rollment is anticipated to continue until November 2020. The trial has 
been registered in clinicaltrials.gov (https://clinicaltrials.gov/ct2/ 
show/NCT04486508). 
2.2. Inclusion and exclusion criteria 
In brief, adult hospitalized critically-ill patients with reverse tran-
scription polymerase chain reaction (RT-PCR)confirmed diagnosis of 
COVID-19 within 7 days before the index presentation who do not have 
a history of recent major bleeding, bleeding diathesis, or an existing 
indication for therapeutic anticoagulation and have and estimated 
survival of at least 24 h will be considered for inclusion for the antic-
oagulation hypothesis. Patients enrolled in the anticoagulation study 
will be considered for eligibility for the second randomization to ator-
vastatin versus placebo. Major exclusion criteria for the second ran-
domization consist of baseline routine use of statins, severe liver dis-
ease, and prior history of statin intolerance. Details regarding the 
inclusion and exclusion criteria are summarized in Table 1 and the 
study flow diagram (Fig. 1). 
2.3. Intervention(s) and comparator(s) 
For the INSPIRATION hypothesis, the study intervention is inter-
mediate-dose anticoagulation. The anticoagulant regimen will be 
modified according to weight/body mass index, and creatinine clear-
ance. Enoxaparin will be the primary agent for anticoagulation, with 
unfractionated heparin reserved only for patients with creatinine 
clearance of ≤15 mL/min according to Cockcroft-Gault Formula. 
Standard-dose prophylaxis was defined as enoxaparin 40 mg/day, un-
less adjusted for obesity or creatinine clearance. Details about the 
dosing algorithm for each arm is summarized in Table 2. Intermediate 
dosing was chosen since it was thought by the steering committee to 
have the potential to confer benefit while mitigating the high risk of 
bleeding associated with higher doses of therapeutic anticoagulation 
[35]. This choice was also in line with group consensus of the Global 
COVID-19 Thrombosis Collaborative Group for research priorities [8]. 
For the INSPIRATION-S hypothesis, the study intervention is statin 
therapy with atorvastatin 20 mg once daily. Subjects will be rando-
mized in a double-blind fashion to atorvastatin versus matching pla-
cebo. The dose of atorvastatin was chosen with consideration for con-
comitant antiviral therapies for COVID-19 that may significantly 
interact with higher intensities of statin therapy [36]. 
2.4. Screening and randomization 
A site physician at each of the recruiting hospitals will evaluate 
daily the newly admitted patients to the intensive care units (ICU). 
Patients meeting the eligibility criteria, will be randomized with a web- 
based randomization scheme in permutated blocks of four. The allo-
cation sequence will remain concealed. 
The first randomization will occur for the anticoagulation hypoth-
esis (intermediate dose versus standard dose anticoagulation). 
Afterwards, on the electronic web-based randomization system, sub-
jects will be screened for second randomization (atorvastatin 20 mg 
daily versus matching placebo). If patients meet the eligibility criteria 
for the second randomization, they will be randomized for the second 
hypothesis (statin therapy) stratified by the anticoagulation arm 
(Fig. 1). The randomization schedule was generated by an independent 
biostatistician, not otherwise part of the study team. 
2.5. Study endpoints 
The primary endpoint used for both randomizations is a composite 
of adjudicated acute arterial thrombosis, VTE, undergoing extra-
corporeal membrane oxygenation (ECMO), or all-cause death within 
30 days from enrollment. No systematic screening is planned for VTE, 
and testing will be at the discretion of the treating physicians. Only 
objectively-confirmed VTE events will be sent for blinded adjudication. 
All-cause mortality has been shown to be common in hospitalized pa-
tients with COVID-19 in Iran [37] and expected to be even more 
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common among critically-ill patients. The decision to include ECMO in 
the primary endpoint was for robustness. Use of ECMO, albeit rare in 
the enrolling sites, indicates marked clinical deterioration. In addition, 
it necessitates (more than prophylactic) anticoagulation. For these 
reasons, the steering committee made an a priori decision to use it as a 
component of the primary endpoint (rather than an issue causing pro-
tocol non-adherence). 
The main secondary efficacy endpoints include all-cause mortality, 
adjudicated VTE, and ventilator-free days. Key safety endpoints include 
major bleeding according to the Bleeding Academic Research 
Consortium definition [38], clinically-relevant non-major bleeding, and 
severe thrombocytopenia (platelet count < 20,000/fL) for the antic-
oagulation hypothesis. For the statin hypothesis, the main safety end-
points include rise in liver enzymes > 3 times upper normal limit, and 
clinically-diagnosed myopathy (Fig. 1). Study endpoints and their de-
finitions are summarized in Table 3. 
During the assessment of the design paper and while the trial has 
been ongoing, the study group received feedback for considering the 
assessment of functional status in patients who survived to hospital 
discharge. The steering committee decided to consider the inclusion of 
the Post-COVID-19 Functional Status (PCFS) scale [39] for post-dis-
charge and 1-month follow-up interviews for the second half of the 
enrollment period. 
All serious adverse events and clinical endpoints will be assessed 
and adjudicated by a centralized Clinical Events Committee which will 
meet online on a weekly basis and adjudicate the events, blinded to the 
treatment assignments. 
2.6. Other data elements 
Other data elements in the study include the demographics, co- 
morbid conditions (including history of diabetes, hypertension, cor-
onary or peripheral arterial disease, heart failure, and venous throm-
bosis). Prior use of statins and medications working on the renin-an-
giotensin-aldosterone system will be ascertained. The Acute Physiology 
and Chronic Health Evaluation II (APACHE II) score will be calculated 
at the time of ICU admission. Laboratory tests of interest include 
baseline and nadir hemoglobin and platelet counts, as well as plasma 
creatinine values. In centers where digital electrocardiograms are 
available, an electrocardiogram will be recorded for future exploratory 
analyses. Key concomitant medical therapies including use and dose of 
corticosteroids, antiviral therapies, antiplatelet agents, ascorbic acid 
and colchicine, will be recorded. 
2.7. Data abstraction and entry 
During the course of ICU stay or de-escalation of care to medical 
wards, a dedicated site physician will continue to monitor each patient 
and extract the necessary data elements. In case of hospital discharge, 
regular weekly phone interviews will be performed until 30 days from 
enrollment or death, whichever that occurs first. If phone interview is 
indicative of a hospitalization or a serious adverse event, additional 
records will be requested. Data will be entered into standardized case 
report forms and subsequently entered into an online database. Periodic 
site visits will ensure appropriate screening and data entry into case 
report forms. Electronic data entry will be double-checked by a separate 
monitor. 
2.8. Statistical analysis 
Categorical variables will be reported as frequency counts (per-
centages and 95% confidence intervals). Continuous data will be sum-
marized as mean and standard error of the mean, or median with 25/75 
interquartile ranges (if not normally distributed). 
The primary efficacy analyses will be performed in the modified 
intention-to-treat (mITT) cohort, consisting of patients without post- 
randomization exclusion (e.g., due to withdrawal of consent) who re-
ceived at least one dose of their assigned treatment. Sensitivity analyses 
will be performed in the pure ITT and per-protocol cohorts. The per- 
protocol cohort is defined as patients who received the assigned treat-
ment until the end of the study or until reaching a component of the 
primary endpoint, whichever occurred earlier. The primary safety 
analyses will be performed among patients who received at least one 
dose of the study drugs, and will be repeated in the per-protocol cohort. 
For assessment of both hypotheses, a test of interaction will be 
performed between anticoagulation regimen and statin therapy with 
the primary outcome. If the test of interaction is negative (P  <  0.05), 
the two hypotheses will be tested independently. 
A two-sided alpha of 0.05 will be considered for both study hy-
potheses. Sample size estimates are based on the z approximation for-
mula for the comparison of proportions between two different groups. 
For the anticoagulation hypothesis, based on the estimates from site 
investigators in the enrolling centers, the primary endpoint event rate 
for the standard dose group was estimated at 55%. Considering an 
absolute risk reduction of 12% in the primary endpoint in the inter-
mediate dose group, the study will need a total of 544 patients to have 
80% power to detect a significant difference between the two study 
groups. Considering that there may be a 10% dropout rate (for example 
due to withdrawal of consent, or no use of the study drugs), we decide 
to enroll 600 patients for the anticoagulation hypothesis. In addition, a 
prespecified secondary analysis for non-inferiority will be performed 
for major bleeding in patients receiving intermediate-dose versus 
standard dose pharmacological prophylaxis. Considering event rates of 
5.5% and 6.5% in standard dose and intermediate dose anticoagulation 
arms respectively for major bleeding [35,40], and a non-inferiority 
margin of 1.8 as odds ratio, the study would have 80% power to detect 
the non-inferiority of intermediate-dose anticoagulation. Pre-specified 
analyses will be performed based on sex, age, weight, history of hy-
pertension, the APACHE II score, and baseline D-dimer. 
For the statin hypothesis, the sample size is estimated to be 30% less 
than the original sample size of the anticoagulation hypothesis. This 
will be due to systematic exclusion of patients who were on statins at 
baseline or those who meet other exclusion criteria for the statin ran-
domization (Table 1). As such, considering 600 patients for enrollment 
in the anticoagulation hypothesis will yield 420 patients for the statin 
hypothesis. With a control arm event rate of 55% and an estimated 
relative risk reduction of 25% with statin therapy for the primary 
endpoint, the study will have 69% power to detect a significant dif-
ference for the statin hypothesis. At the determination of the steering 
committee, if patient enrollment is found to be continually feasible with 
respect to the disease wave and logistics at enrolling centers, it has been 
specified a priori that enrollment could be extended, with no interim 
efficacy analyses, until the second randomization has 80% power to 
detect a significant difference for the primary endpoint. For this pur-
pose, 124 additional patients would need to be recruited for the statin 
randomization. 
In accord with guidelines from the European Medicine Agency 
(https://www.ema.europa.eu/en/documents/scientific-guideline/ 
guideline-adjustment-baseline-covariates-clinical-trials_en.pdf) and 
given that no other completed randomized trials for antithrombotic 
therapy in COVID-19 are available to advise on baseline covariates, we 
decided to use unadjusted models for the primary analysis for the an-
ticoagulation hypothesis. In turn, for the statin hypothesis, the primary 
analysis will be adjusted for the stratification variable (i.e., antic-
oagulation arm). Since the event rates are assumed to accrue non-pro-
portionally, Cox-proportional hazard models will not be used for pri-
mary analysis. Rather, logistic regression models with odds ratio as the 
effect measure will be used for primary analyses. However, Kaplan 
Meier plots will be used for graphical representation of the events in 
each arm considering the time to reaching the primary endpoint. 
Models will be repeated with Cox-proportional hazard models for sen-
sitivity analysis. Statistical analyses will be performed via R statistical 
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software package (R Core Team, Vienna, Austria). 
2.9. Study oversight 
The safety oversight will be under the direction of the Data and 
Safety Monitoring Board (DSMB) whose members are not part of the 
authors group. The DSMB members have full access to the study data, 
with help from an independent statistician, as well as all the reports by 
the Clinical Events Committee. 
To provide the most informative results, without risking the possi-
bility of an overinflated estimate of the effect size, the steering com-
mittee decided not to set pre-specified criteria for early termination for 
efficacy [41]. Similarly, the steering committee specified not to stop the 
trial prematurely for futility, unless further recruitment seemed un-
feasible due a change in the disease wave or logistical limitations at 
enrolling centers, in which case the DSMB will make a determination of 
futility based on conditional probability. 
With respect to stopping considerations for harm, the DSMB will 
perform analyses after recruitment of 25%, 50%, and 75% of the target 
population to indicate whether a significant increase in the primary 
composite endpoint or in all-cause mortality for intermediate-dose an-
ticoagulation arm has occurred, compared with the standard-dose 
prophylaxis arm with a P-value threshold of 0.01. Bleeding events may 
become more frequent with intermediate-dose anticoagulation com-
pared with standard-dose anticoagulation. To consider early stopping 
for harm, an absolute 10% excess in bleeding events, with two-sided P- 
value of 0.016 (0.05 divided by 3, the number of interim analyses) will 
be required. Early termination for harm will be contingent on the ab-
sence of a counterbalancing efficacy improvement at the discretion of 
the DSMB. Criteria for early stopping due to harm for the antic-
oagulation randomization and for statin randomization also include an 
excess in the primary endpoint or all-cause mortality, with a P-value 
threshold of 0.01. The DSMB will communicate safety concerns or other 
oversight issues with the study principal investigators (PS and BB). 
3. Discussion 
This manuscript summarizes the methodological features of the 
INSPIRATION and INSPIRATION-S studies. With the increasing medical 
and economic devastation of COVID-19, it is imperative to identify safe 
and effective therapies to mitigate patient outcomes. Besides the pro-
mising results with dexamethasone [42] and remdesivir [43], no other 
therapies have shown benefits for patients with severe COVID-19. 
The INSPIRATION study can further elucidate whether intermediate 
dose anticoagulation can confer benefit, primarily by reducing the 
thrombotic event rates, and thereby mortality. Several ongoing rando-
mized trials are trying to address the potential utility of various in-
tensities of antithrombotic agents for patients with COVID-19. Fig. 2 
summarizes the list of randomized trials of anticoagulant therapy for 
COVID-19 registered at clinicaltrials.gov by August 14, 2020. These 
studies span a wide range of outpatient and inpatient illness severity for 
patients with COVID-19. The vast majority of these trials excludes pa-
tients who require therapeutic anticoagulation or those with high risk 
of bleeding, although the definition of the latter is variably defined 
across these trials. 
In turn, the hypothesis tested in INSPIRATION-S will assess whether 
targeting thromboinflammatory pathways with atorvastatin has the 
potential to mitigate the clinical outcomes [44,45]. Results from several 
additional ongoing statin trials (Fig. 3) will be informative in this re-
gard. 
The database may also lend support to additional ancillary analyses 
from this cohort of prospectively enrolled patients. Such analyses may 
include studies to explore the association between baseline use of renin- 
angiotensin-aldosterone antagonists and outcomes, machine learning 
algorithms to identify electrocardiographic features predictive of ad-
verse outcomes, or subgroup analyses based on disease severity (such as 
the APACHE II score) on clinical outcomes. 
Some design aspects of this randomized trial deserve further at-
tention. Considering the unique situations caused by the COVID-19 
pandemic, the study was designed in an extraordinarily short period of 
time, with time from inception of the idea to enrollment of the first 
patient in only 25 days. The pragmatic features of the study facilitated 
the timeliness of the process. In the face of the pandemic, most meet-
ings, including those by the Clinical Events Committee, and those by 
the DSMB will be held online. Such approaches may also improve the 
efficiency of monitoring and communications. 
Although INSPIRATION and INSPIRATION-S may help provide 
important information for management of patients with severe COVID- 
19, the limitations should be noted. First, due to time constraints and 
logistical challenges, it was not feasible to consider international pa-
tient recruitment. Second, the focus of both studies is on critically-ill 
patients with COVID-19. Therefore, generalizability will be limited to 
studies of critically-ill patients. Additional ongoing trials can determine 
the utility of other antithrombotic regimens among hospitalized pa-
tients with COVID-19 in medical wards, or among outpatients (Fig. 2). 
Third, INSPIRATION/INSPIRTION-S will be focusing on short-term (30- 
day outcomes). Although longer-term follow-up is desirable, the period 
of hospitalization and the early post-discharge phase are highest risk 
periods for the explored study endpoints. If additional funding and 
resources become available, we may expand the follow-up for up to 60 
or 90 days. Finally, INSPIRATION will be an open-label pragmatic 
study. In depth discussions in the steering committee found it un-
feasible to consider a double-blind double dummy design. Nevertheless, 
all outcomes will be adjudicated by the clinical events committee 
blinded to group assessment. The INSPIRATION-S study, in turn, will be 
double-blinded. 
In conclusion, the INSPIRATION and INSPIRATION-S studies will 
help determine whether intermediate-dose anticoagulation or use of 
atorvastatin 20 mg daily can confer benefit in critically-ill patients with 
COVID-19. Preliminary results may be available before the end of 2020. 
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